Design and Construction of a Radiochemistry Laboratory and cGMP-Compliant Radiopharmacy Facility

Author:

Asor Angela12ORCID,Metebi Abdullah134,Smith Kylie15,Last Kurt6,Strauss Elaine6,Fan Jinda125ORCID

Affiliation:

1. Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA

2. Department of Chemistry, Michigan State University, East Lansing, MI 48824, USA

3. Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824, USA

4. Radiological Science Department, Taif University, Taif 21944, Saudi Arabia

5. Department of Radiology, Michigan State University, East Lansing, MI 48824, USA

6. WorkingBuildings, Atlanta, GA 30309, USA

Abstract

The establishment of a compliant radiopharmacy facility within a university setting is crucial for supporting fundamental and preclinical studies, as well as for the production of high-quality radiopharmaceuticals for clinical testing in human protocols as part of Investigational New Drug (IND) applications that are reviewed and approved by the U.S. Food and Drug Administration (FDA). This manuscript details the design and construction of a 550 ft2 facility, which included a radiopharmacy and a radiochemistry laboratory, to support radiopharmaceutical development research and facilitate translational research projects. The facility was designed to meet FDA guidelines for the production of aseptic radiopharmaceuticals in accordance with current good manufacturing practice (cGMP). A modular hard-panel cleanroom was constructed to meet manufacturing classifications set by the International Organization of Standardization (ISO), complete with a gowning room and an anteroom. Two lead-shielded hot cells and two dual-mini hot cells, connected via underground trenches containing shielded conduits, were installed to optimize radioactive material transfer while minimizing personnel radiation exposure. Concrete blocks and lead bricks provided sufficient and cost-effective radiation shielding for the trenches. Air quality was controlled using pre-filters and high-efficiency particulate air (HEPA) filters to meet cleanroom ISO7 (Class 10,000) standards. A laminar-flow biosafety cabinet was installed in the cleanroom for preparation of sterile dose vials. Noteworthy was a laminar-flow insert in the hot cell that provided a shielded laminar-flow sterile environment meeting ISO5 (class 100) standards. The design included the constant control and monitoring of differential air pressures across the cleanroom, anteroom, gowning room, and controlled research space, as well as maintenance of temperature and humidity. The facility was equipped with state-of-the-art equipment for quality control and release testing of radiopharmaceuticals. Administrative controls and standard operating procedures (SOPs) were established to ensure compliance with manufacturing standards and regulatory requirements. Overall, the design and construction of this radiopharmacy facility exemplified a commitment to advancing fundamental, translational, and clinical applications of radiopharmaceutical research within an academic environment.

Funder

Michigan State University Startup Funding

HFHS-MSU Seed Funding

MSU-Spectrum Alliance

NIH

Publisher

MDPI AG

Reference14 articles.

1. (2024, April 21). 21 CFR Part 212-Current Good Manufacturing Practice for Positron Emission Tomography Drugs, Available online: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-212.

2. Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations;Bunning;J. Nucl. Med.,2022

3. Food and Drug Administration, HHS (2009). Current good manufacturing practice for positron emission tomography drugs. Fed. Regist., 74, 65409–65436. (In English).

4. (2024, April 21). Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice, Guidance for Industry, Available online: https://www.fda.gov/media/71026/download.

5. (2024, April 21). 21 CFR Part 211-Current Good Manufacturing Practices for Finished Pharmaceuticals, Available online: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3